Abstract
Dear Editor, we read the publication on “The expression of RUNX3 gene in renal cell cancer and its clinical relevance with serum vascular endothelial growth factor” with a great interest. Parmar <em>et al</em>. concluded that “Lower expression of RUNX3 in renal cancer suggests its tumor suppressive role”. In fact, the role of RUNX3 is well clarifi d in several malignancies. It is no doubt there is the similar observation for the case of renal cell carcinoma. In the present report, there are some limitations as noted by Parmar <em>et al</em>. An important consideration is the possible concurrent effect of another genetic factor that might modify the fi phenotypic manifestation. In case of RUNX3, the effect of concurrent p53 is well clarifi and should be studied.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Molecular and Immuno Oncology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
